Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of cabiralizumab alone or with nivolumab in advanced malignancies
jRCT2080223582Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabiralizumab and nivolumab in Non-hematologic malignancy and multiple myeloma (MM) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of cabiralizumab alone and in combination with nivolumab and Maximum tolerated dose / recommended dose. Started Jul 2017; status: completed.
02
Drugs
cabiralizumabnivolumab
03
Conditions
Non-hematologic malignancymultiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080223582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223582.